Korsukewitz, Catharina
Reddel, Stephen W.
Bar-Or, Amit
Wiendl, Heinz http://orcid.org/0000-0003-4310-3432
Article History
Accepted: 17 June 2020
First Online: 8 July 2020
Change Date: 22 July 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41582-020-0392-9
Competing interests
: C.K. has received travel support and/or speaking honoraria from Biogen, Sanofi Genzyme, Roche, Merck and Teva within the past years. S.R. has received funds within the past 5 years for (but not limited to) travel support, honoraria, trial payments, research and clinical support to the neurology department of which he is a member from several bodies and charities such as Lambert Initiative, Beeren Foundation and anonymous donors, and from Baxter, Bayer Schering, Biogen Idec, CSL, Sanofi Genzyme, Grifols, Octapharma, Merck, Novartis, Roche, Sanofi Aventis Genzyme, Servier and Teva. S.R. also declares the following competing interests: co-founder and shareholder of Medical Safety Systems trading as RxMx (including grant and/or contracts with Genzyme, Novartis, Roche and Janssen); receives payment for contributions to the National IVIg Governance Advisory Council & Specialist Working Group Australia (Neurology) and the Australian Medical Services Advisory Committee ad hoc sub-committee on IVIg; unpaid member of the Australian Technical Advisory Group on Immunization Varicella Zoster working party; receives a public salary as a staff specialist neurologist from Concord Hospital Sydney Local Health District; receives private billings from patients and Medicare Australia reimbursement as a private practice neurologist; and is an unpaid medical adviser to various patient and advocacy groups. A.B.-O. serves on scientific advisory boards for Atara Biotherapeutics, Biogen Idec, Celgene/Receptos, Janssen/Actelion, Merck/EMD Serono, Novartis, Roche/Genentech and Sanofi Genzyme, and has sponsored research agreements with Biogen Idec, Novartis and Roche/Genentech. H.W. receives honoraria for acting as a member of scientific advisory boards for Biogen, Evgen, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma AG and Sanofi-Aventis, as well as speaker honoraria and travel support from Alexion, Biogen, Cognomed, F. Hoffmann-La Roche, Gemeinnützige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma AG, Genzyme, Teva and WebMD Global. H.W. is also a paid consultant for Abbvie, Actelion, Biogen, IGES, Johnson & Johnson, Merck, Novartis, Roche and Sanofi. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, the European Union, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and RE Children’s Foundation, Biogen, GlaxoSmithKline GmbH, Roche Pharma AG and Sanofi Genzyme.
Free to read: This content has been made available to all.